Related Experiment Video

Updated: Aug 1, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.0K

How specific molecular-targeted agents can make obsolete a 'one size fits all' approach in EGFR-mutated NSCLC

Carmen Popescu1, Laura Mazilu2, Andra-Iulia Suceveanu3

  • 1Doctoral School, 'Carol Davila' University of Medicine and Pharmacy, 050474 Bucharest, Romania.

Experimental and Therapeutic Medicine
|September 10, 2021
PubMed

Insights

Lung cancer has high mortality despite advances. Personalized treatment using tyrosine kinase inhibitors (TKIs) shows promise for EGFR-mutated lung cancer, but overcoming resistance requires further research.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Lung cancer remains a leading cause of cancer mortality globally.
  • Despite treatment advances, high mortality persists due to disease aggressiveness and diagnostic challenges.
  • Personalized medicine necessitates integrating molecular and genetic tumor profiling into diagnostics.

Purpose of the Study:

  • To review the impact of tyrosine kinase inhibitors (TKIs) on EGFR-mutated lung cancer.
  • To highlight the significance of molecular aberrations and tumor genetics in treatment decisions.
  • To emphasize the need for research into TKI combination strategies to overcome resistance.

Main Methods:

  • Review of current literature on lung cancer treatment and molecular targeted therapies.
  • Analysis of the role of EGFR mutations and TKI efficacy in non-small cell lung cancer (NSCLC).
  • Discussion of ongoing clinical trials for advanced or metastatic NSCLC with EGFR mutations.

Main Results:

  • Tyrosine kinase inhibitors (TKIs) have improved survival for patients with EGFR mutations.
  • EGFR mutations are key predictive factors for TKI treatment outcomes in adenocarcinoma.
  • Further research into TKI combinations is crucial for addressing treatment resistance.

Conclusions:

  • Personalized treatment strategies incorporating molecular profiling are essential for lung cancer management.
  • Targeted therapies like TKIs offer improved outcomes for specific patient subgroups.
  • Ongoing clinical trials are expected to refine therapeutic approaches for EGFR-mutated NSCLC.
Keywords:
EGFR mutationsnon-small cell lung cancerprogression-free survivaltarget therapiestyrosine kinase inhibitors

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.3K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.3K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...